<DOC>
	<DOCNO>NCT01121913</DOCNO>
	<brief_summary>The objective study : - compare pharmacokinetic profile two prototype controlled-release ( CR ) trazodone hydrochloride ( HCl ) 300 mg tablet versus two reference product : Trittico® AC ( 2 x 150 mg CR tablet ) Desyrel® ( 3 x 100 mg IR ( immediate-release ) tablet ) fast condition ; - ass control release property two prototype formulation ; - select prototype formulation development ; - validate blood sample schedule future pivotal pharmacokinetic study ; - determine appropriate sample size pivotal study base intra-subject variability .</brief_summary>
	<brief_title>Comparative Bioavailability Study Two Prototypes Trazodone Controlled-release Products Two Marketed Reference Products Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Trazodone</mesh_term>
	<criteria>Healthy male female subject 18 45 year age ( inclusive ) . Body mass within 10 % ideal mass relation height age , accord BMI . Body mass le 70 kg . The normal total circulate blood volume male females 71 mL/kg 65 mL/kg body mass , respectively ( Meyer , 1988 ) . No subject 13 % estimate blood volume take study ( Standards Practice Blood Transfusion South Africa , 1999 ) . Findings within range clinical acceptability medical history physical examination , laboratory result within `` normal range '' relevant laboratory test ( unless clinical investigator considers deviation irrelevant purpose study ) . Normal ECG vital sign , abnormality clinical investigator consider disqualification participation study . Willingness undergo pre poststudy physical examination , pre post study laboratory investigation . Ability comprehend willingness sign statement inform consent ( screen phaserelated procedure ) . Nonsmoker past smoker stop smoke least 3 month enter study . For female , follow condition meet : 1. surgically sterilize , 2. childbearing potential , follow condition meet : 1. normal menstrual flow within 1 month study entry , 2. negative urine pregnancy test screening . If test positive , subject exclude study receive study medication . In rare circumstance pregnancy discover subject receive study drug , every attempt must make follow subject term , 3. must agree use accepted method contraception ( i.e. , spermicide barrier method spermicide intrauterine contraceptive device ) . The subject must agree continue method throughout study . Hormonal contraceptive allow , stable dose least one month prior first intake study medication . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . History , current compulsive alcohol abuse ( &gt; 10 drink weekly ) , regular exposure substance abuse . Use medication , prescribed overthecounter , within 2 week prior first administration study medication except affect outcome study opinion clinical investigator . Use hormonal contraceptive agent females allow . Participation another study experimental drug within 8 week first administration study medication . Treatment within previous 3 month drug welldefined potential adversely affect major organ system evidence effect . A major illness 3 month commencement screening period . History hypersensitivity study drug relate drug . History bronchial asthma . History epilepsy . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 mL 8 week first administration study medication . Diagnosis hypotension make screening period . Diagnosis hypertension make screening period current diagnosis hypertension . Resting pulse rate &gt; 100 beat per minute &lt; 45 beat per minute screening period , either supine standing . Positive test HIV , hepatitis B surface antigen and/or Hepatitis C antibody . Positive urine screen drug abuse . A urine pregnancy test ( ßHCG ) either positive perform lactation . Positive urine screen tobacco use ( SureStepTM Smoke Check Tests OneStep Cotinine ( COT ) Tests ) . History marijuana , barbiturate , amphetamine narcotic abuse within 12 month prior study start . Significant liver disease , define active hepatitis elevate liver enzymes ( e.g . aspartate aminotransferase , alanine aminotransferase ) &gt; 2 time upper boundary normal range .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Healthy subject</keyword>
</DOC>